NeuroCytonix Autism Forum

Washington, DC – March 11, 2026— Parents, researchers, and advocates gathered at the Cosmos Club for an evening of discussion on advanced approaches to autism spectrum disorder (ASD), a condition estimated to affect 1 in 36 eight-year-olds. Hosted by NeuroCytonix, the event highlighted Functional Neurogenesis Stimulation (FNS)—the company’s novel technology that is being studied for its potential role in supporting brain repair and its possible impact on communication, learning, and behavioral development in people with ASD.

The evening began with a welcoming reception featuring live music by Dr. Shearom Chung, a talented violinist, setting the tone for an engaging discussion. NeuroCytonix’s CFO and COO Laurent Lavigne du Cadet opened the session, followed by an inspiring perspective from Michael Batt, a global business leader who shared his experience with the technology and its potential.

Dr. J. Roberto Trujillo, Founder and CEO of NeuroCytonix, took the stage next to provide deeper insights into ASD and the research his team is focusing on. He spoke about the upcoming clinical trials, which aim to evaluate the safety, preliminary efficacy, and feasibility of FNS for ASD.

Later in the program, Goli Jabbari and her son, Cameron Parvizian, shared a moving testimonial, highlighting their experience participating in NeuroCytonix’s open-label research study exploring the technology and its potential effects.

Attendees included key representatives from Morgan Stanley Investment Management and the U.S. Department of Health and Human Services. The event served as a platform for learning, collaboration, and discussions on the evolving landscape of autism research. The evening concluded with an open discussion, allowing parents to connect, ask questions, and explore potential next steps.